Molecule
Betamethasone dipropionate is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. MedsAcross supplies Betamethasone dipropionate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Augmented Betamethasone Dipropionate Ointment is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. Augmented Betamethasone Dipropionate Ointment is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older.
Source: US FDA prescribing information
Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation, however, the precise mechanism of action of Augmented Betamethasone Dipropionate Ointment in corticosteroid responsive dermatoses is unknown.
Source: US FDA prescribing information
Apply a thin film of Augmented Betamethasone Dipropionate Ointment to the affected skin areas once or twice daily. Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Augmented Betamethasone Dipropionate Ointment is a super-high-potency topical corticosteroid. Treatment with Augmented Betamethasone Dipropionate Ointment should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Augmented Betamethasone Dipropionate Ointment should not be used with occlusive dressings unless directed by a physician. Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site. Avoid contact with eyes. Wash hands after each application. Augmented Betamethasone Dipropionate Ointment is for topical use only.
Source: US FDA prescribing information
Augmented Betamethasone Dipropionate Ointment is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation. Hypersensitivity to any component of this medicine.
Source: US FDA prescribing information
Effects on endocrine system: Augmented Betamethasone Dipropionate Ointment can cause reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency during and after withdrawal of treatment. Risk factor(s) include the use of high-potency topical corticosteroids, use over a large surface area or to areas under occlusion, prolonged use, altered skin barrier, liver failure, and use in pediatric patients. Modify use should HPA axis suppression develop. Ophthalmic Adverse Reactions: Augmented Betamethasone Dipropionate Ointment may increase the risk of cataracts and glaucoma. If visual symptoms occur, consider referral to an ophthalmologist for evaluation.
Source: US FDA prescribing information
Most common adverse reactions (<1%) are: erythema, folliculitis, pruritus, and vesiculation.
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
8 presentations of Betamethasone dipropionate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Betamethasone dipropionate 0.05% creamTopicalGeneric name | — | US FDA | Available on request |
| Betamethasone dipropionate 0.05% ointmentTopicalGeneric name | — | US FDA | Available on request |
| Betamethasone dipropionate 0.5 mg/mL lotionTopicalGeneric name | — | US FDA | Available on request |
| Betamethasone dipropionate 0.05% gelTopicalGeneric name | — | US FDA | Available on request |
| Betamethasone dipropionate 0.5 mg/g topical sprayTopicalGeneric name | — | US FDA | Available on request |
| Diprolene 0.05% ointmentTopical | Organon | US FDA | Available on request |
| Sernivo 0.5 mg/g topical sprayTopical | Primus Pharmaceuticals | US FDA | Available on request |
| Betamethasone dipropionate 0.05% lotionTopicalGeneric name | — | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 29 January 1975 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 8 presentations of Betamethasone dipropionate and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Betamethasone dipropionate, including Diprolene, Sernivo.
Yes. The US FDA first approved Betamethasone dipropionate on 29 January 1975, according to Drugs@FDA.
No listed presentation of Betamethasone dipropionate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.